Cytoflavin in the Complex Rehabilitation of Stroke Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

December 7, 2024

Conditions
Stroke
Interventions
DRUG

Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)

Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days

DRUG

Placebo

Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days

Trial Locations (3)

Unknown

City General Hospital №2, Saint Petersburg

City Hospital №40 of the Kurortny District, Saint Petersburg

Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine, Saint Petersburg

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT05935787 - Cytoflavin in the Complex Rehabilitation of Stroke Patients | Biotech Hunter | Biotech Hunter